<DOC>
	<DOCNO>NCT00112658</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . It yet know chemotherapy regimen effective first-line therapy treat pancreatic cancer . PURPOSE : This randomized phase II/III trial study well combination chemotherapy work first-line therapy treat patient metastatic pancreatic cancer .</brief_summary>
	<brief_title>Combination Chemotherapy First-Line Therapy Treating Patients With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare objective response rate patient metastatic adenocarcinoma pancreas treat oxaliplatin , irinotecan , leucovorin calcium , fluorouracil vs gemcitabine first-line chemotherapy . ( Phase II ) - Compare survival patient treat regimen . ( Phase III ) Secondary - Compare toxicity regimens patient . - Compare progression-free survival patient treat regimen . ( Phase III ) - Compare overall response rate patient treat regimen . ( Phase III ) - Compare quality life patient treat regimen . ( Phase III ) OUTLINE : This randomize , multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oxaliplatin IV 2 hour , irinotecan IV 1½ hour , leucovorin calcium IV 2 hour , fluorouracil IV 5 minute day 1 fluorouracil IV continuously 46 hour day 1 2 . Courses repeat every 14 day . - Arm II : Patients receive gemcitabine IV day 1 , 8 , 15 , 22 , 29 , 36 , 43 . Beginning day 57 , patient receive gemcitabine IV weekly 3 week ( day 57 , 64 , 71 ) . Courses repeat every 28 day . PROJECTED ACCRUAL : A total 348 patient ( 88 phase II 260 phase III ) accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma pancreas No pancreatic tumor type , include either follow : Neuroendocrine tumor Acinar cell tumor Metastatic disease Measurable disease area previously irradiate No cerebral metastasis meningeal involvement tumor PATIENT CHARACTERISTICS : Age 18 75 Performance status WHO 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin ≤ 1.5 time upper limit normal ( biliary drainage allow ) Renal Creatinine &lt; 120 mmol/L Cardiovascular No prior myocardial infarction No prior angina No uncompensated cardiac coronary insufficiency No symptomatic arrhythmia Gastrointestinal No prior inflammatory bowel disease No prior chronic diarrhea No unresolved symptomatic occlusion subocclusion bowel Other Not pregnant nursing Fertile patient must use effective contraception No ongoing active infection No malignancy except basal cell squamous cell skin cancer carcinoma situ cervix No contraindication study treatment No serious medical disorder would preclude study treatment No psychiatric disorder social geographic situation would preclude study participation Not detain guardianship another person PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy Surgery Not specify Other No concurrent participation another clinical trial use therapeutic experimental agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>